Journal
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
Volume 14, Issue 3, Pages 311-324Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14787210.2016.1138857
Keywords
levofloxacin; ketolide; solithromycin; Streptococcus pneumoniae; Legionella pneumophila; Haemophilus influenzae; Mycoplasma pneumoniae; moxifloxacin; Chlamydophila pneumoniae; community-acquired bacterial pneumonia
Funding
- Cempra
Ask authors/readers for more resources
The fluoroketolide solithromycin is 2-fold more potent in vitro than telithromycin against pneumococci (including macrolide-resistant strains) and Haemophilus influenzae and very active on pathogens causing atypical pneumonia. In contrast, it is a 30-fold less potent inhibitor of nicotinic receptors incriminated in telithromycin toxicity. In Phase II/III trials, oral solithromycin once-daily (800 mg on day 1; 400 mg on days 2-5) proved effective and safe when compared to respiratory fluoroquinolones for the treatment of community-acquired bacterial pneumonia (CABP). A Phase III intravenous trial vs. moxifloxacin has been recently completed for the same indication. Solithromycin may restore interest in ketolides as a first-line therapy for CAPB. Solithromycin safety should nevertheless be confirmed in larger populations allowing for detection of rare adverse events.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available